news

BioDuro Appoints Dr. Andrew Thomas and Dr. Stevan Djuric as Scientific Advisors

BioDuro, a leading global contract research, development, and manufacturing organization (CRDMO), today announced the appointment of Andrew Thomas, Ph.D., and Stevan Djuric, Ph.D., as scientific advisors. In these new roles, they will provide strategic guidance to clients, and BioDuro’s scientific and operational teams, helping strengthen the company’s capabilities in innovative drug discovery and development.
March 12, 2026

BioDuro and Cenra Launch Joint Venture to Expand Resilient Global API Manufacturing Capacity

IRVINE, California, March 3, 2026 – BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has established a joint venture with Cenra API Solutions, also as known as Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB), a leading pharmaceutical chemical manufacturer in Taiwan since 1964, to add significant commercial-scale active pharmaceutical ingredient (API) manufacturing capacity at Cenra's campus in Taipei, Taiwan, to BioDuro's global network.
March 03, 2026

BioDuro Once Again Named 2025 Best CRO by Daewoong Pharmaceutical

February 2026 — BioDuro has once again been honored with the 2025 Best CRO Award by Daewoong Pharmaceutical (DAEWOONG BIO INC., South Korea), recognizing its excellence among within Daewoong's global network of CRO partners. This repeat recognition reflects Daewoong Pharmaceutical's strong confidence in BioDuro's consistent scientific quality and project delivery.
February 10, 2026

BioDuro Appoints Hong Wan as Senior Vice President of DMPK

We're excited to welcome Dr. Hong Wan to BioDuro as Senior Vice President of DMPK. He will lead our global DMPK and bioanalytical functions, further strengthening our integrated drug discovery cap
January 27, 2026

BioDuro Completes Divestiture of its Drug Product Manufacturing Facility in Irvine, California

IRVINE, Calif. January 12, 2026 – BioDuro, a leading global contract research, development, and manufacturing organization (CRDMO), today announced the completion of the sale of its Irvine-based drug product facility to Forma Life Sciences, Inc., a Delware entity formed by BioSelective Capital Investments and Shayan Enterprises, LLC, for the purpose of the acquisition.
January 12, 2026

Three BioDuro Sites Recognized with EcoVadis Gold and Silver Medals

IRVINE, California, January 5, 2026 – BioDuro, a leading global contract research, development, and manufacturing Organization (CRDMO), today announced that its Shanghai Free Trade Zone (FTZ) site and
January 05, 2026

BioDuro Launches Dedicated Peptide Business Unit, Accelerating Integrated Drug Discovery Solutions

IRVINE, Calif. – November 18, 2025 – BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of a new Business Unit (BU) dedicated to advancing peptide drug discovery and development for its global biopharma partners, underscoring the company's commitment to strengthening its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics, including GLP-1 treatments.
November 18, 2025

BioDuro Appoints Yaohui Ji as Global President, CMC to Accelerate Expansion of Integrated CRDMO Capabilities

IRVINE, Calif. – November 11, 2025 – BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the appointment of Mr. Yaohui Ji as Global Presid
November 11, 2025
Total 106 12345678...1314
✉️Contact Us
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all